Please check back frequently for news, announcements, and events.
June 1, 2021
Praetego Inc, a preclinical stage pharmaceutical company developing novel candidates against chronic diseases of aging, is pleased to announce an award of a $458K grant to study the Amadorin candidates for the treatment of Alzheimer’s Disease.
April 26, 2021
Praetego’s CEO, Pepper Landson, is honored to be invited to Springboard Enterprises’ 2021 Health Innovation Hub: Life Science cohort.
September 30, 2020
Praetego Inc. is pleased to announce the approval of a multi-year $2.1M STTR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. The award advances the Company’s proprietary small molecules for treatment of Diabetic Peripheral Neuropathy (DPN).
March 1, 2020
Praetego will showcase their candidates as potential disease modifying drugs against serious diabetic complications, starting with Diabetic Peripheral Neuropathy. The Amadorins are novel small molecules developed by Praetego scientists and designed from a clinically proven prototype.
February 10, 2020
Praetego co-founder and CEO Pepper Landson sat down with Proactive’s Christine Corrado at BIO CEO in New York.
January 2, 2020
After a successful conclusion of the Phase 1 NIDDK grant, Praetego submits a Phase 2 SBIR/STTR grant to continue preclinical development of novel Amadorins against Diabetic Peripheral Neuropathy. This award would provide preclinical proof of concept in multiple animal models of Type 1 and Type 2 diabetic neuropathy.